Ventricular arrhythmias, Part III: Benefits and risks of antiarrhythmic therapy.
In Parts I and II of this series, clinical significance, prevalence, and special concerns in the evaluation of patients with ventricular arrhythmias were reviewed. We now examine the categories of antiarrhythmic drugs and offer indications for their use. Reasons why a patient may not respond to antiarrhythmic therapy, end points of therapy, and the benefits and drawbacks of measuring serum drug levels are addressed. Use of newer drugs and additional treatment modalities are discussed in the final installment.
Grauer
K
K
University of Florida, College of Medicine, Gainesville.
Gums
J
J
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000145:classification / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000378:metabolism; D006352:Heart Ventricles; D006801:Humans; D008991:Monitoring, Physiologic; D012307:Risk Factors
D000889:Anti-Arrhythmia Agents